http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020227885-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b2e61dd2bca8d3244b7d19b327609dcc |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2740-15043 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-622 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2510-02 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0641 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-86 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2818 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-867 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-10 |
| filingDate | 2019-05-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5ea99c496a63efbc0a4292b8d8889aa0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2fa303cb920db759c22d88ae916cf9c9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_125d0b5b9147af52f825a0e540971ec1 |
| publicationDate | 2020-11-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2020227885-A1 |
| titleOfInvention | Genetically engineered red blood cells carrying anti-pd-1 single-chain antibody and preparation method therefor |
| abstract | Provided are a method for preparing genetically engineered red blood cells carrying an anti-PD-1 single-chain antibody, and genetically engineered red blood cells carrying the anti-PD-1 single-chain antibody. The preparation method comprises the following steps: constructing a target fragment sequence in a lentiviral expression vector; lentivirally packaging a target sequence vector to obtain a high-titer lentiviral concentrate; isolating and enriching Lin-CD34 cells from among peripheral blood mononuclear cells; inducing the Lin-CD34-cells to differentiate into red blood cells and performing amplification thereon; using the lentiviral concentrate to infect the Lin-CD34-cells; and obtaining mature anti-PD-1scFv-red blood cells by means of denucleating red blood cells. The present genetically engineered red blood cells carrying the anti-PD-1 single-chain antibody may perform the targeted delivery of an anti-PD-1 single-chain antibody to tumor tissue. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2023284742-A1 |
| priorityDate | 2019-05-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 354.